Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BCC 2025 | Unanswered questions in managing HER2- early-stage breast cancer

Kevin Kalinsky • 31 Mar 2025
BCC 2025
Breast Cancer

Kevin Kalinsky, MD, MS, Emory University Hospital, Atlanta, GA, comments on the nuances of treating hormone receptor-positive HER2-negative early-stage breast cancer, highlighting the importance of considering geographic variability in treatment approaches and the ongoing debate about the role of ovarian function suppression in postmenopausal patients, particularly those under 40 years of age. CDK4/6 inhibitors offer benefit, but chemotherapy remains a common treatment approach. This interview took place at the 2025 St. Gallen International Breast Cancer Consensus Meeting in Vienna, Austria.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Kevin Kalinsky

Ask the Expert: Kevin Kalinsky answers your breast cancer questions at ESMO 2025
9:15
Ask the Expert: Kevin Kalinsky answers your breast cancer questions at ESMO 2025
Kevin Kalinsky • 20 Oct 2025
Emerging molecular biomarkers in breast cancer from the NATALEE trial
0:58
Emerging molecular biomarkers in breast cancer from the NATALEE trial
Kevin Kalinsky • 2 Jun 2025
Breast cancer updates at ASCO 2025: SERENA-6, DESTINY-Breast09 & ASCENT-04
1:10
Breast cancer updates at ASCO 2025: SERENA-6, DESTINY-Breast09 & ASCENT-04
Kevin Kalinsky • 2 Jun 2025
NATALEE: ribociclib outcomes by menopausal status & age in breast cancer
1:30
NATALEE: ribociclib outcomes by menopausal status & age in breast cancer
Kevin Kalinsky • 2 Jun 2025

Related Videos

Stress and depression linked to tumor transcriptional signatures in breast cancer
1:21
Stress and depression linked to tumor transcriptional signatures in breast cancer
Shipra Gandhi • 31 May 2026
DESTINY-Breast07: final analysis of T-DXd and durvalumab in 1L HER2+ breast cancer
1:13
DESTINY-Breast07: final analysis of T-DXd and durvalumab in 1L HER2+ breast cancer
Shipra Gandhi • 31 May 2026
TBCRC-053: preoperative radiotherapy & pembrolizumab in node-positive TNBC
1:34
TBCRC-053: preoperative radiotherapy & pembrolizumab in node-positive TNBC
Shipra Gandhi • 1 Jun 2026
HELEN-Trio 011: camrelizumab plus chemotherapy as neoadjuvant therapy in TNBC
0:49
HELEN-Trio 011: camrelizumab plus chemotherapy as neoadjuvant therapy in TNBC
Shipra Gandhi • 1 Jun 2026
The content of VJOncology is intended for healthcare professionals